Navigation Links
Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Date:6/2/2008

TSX Venture: QPT

EDMONTON, June 2 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or the "Company"), today announced that its 12-patient, Phase I clinical study entitled "ACP-SL017 Topical Gel: A Phase I Study for the Photodynamic Therapy of Actinic Keratosis" has met both its primary and exploratory objectives.

"We are delighted to have received, for the first time, clinical validation for our SonoLight Technology in a dermatological application," said Madi R. Madiyalakan, CEO of Quest. "Actinic Keratosis is a pre-cancerous skin condition usually caused by prolonged accumulated sun exposure which can progress to squamous cell carcinoma, a potentially life-threatening form of skin cancer, unless treated by a dermatologist or other physician. This trial successfully demonstrated that cutaneous photodynamic therapy (PDT) with SL017 appears safe and is well tolerated. In addition, our unique approach is designed to overcome some of the limitations associated with other commercially available PDT treatments for Actinic Keratosis."

Actinic Keratosis has a global incidence of approximately 10 to 15% in the Caucasian population and the American Medical Association estimates the U.S. market for the treatment of Actinic Keratosis to be about US $250 million.

The primary objective of the Phase I study, which was conducted in Canada, was to determine the cutaneous and systemic toxicity of the topically-applied photoactive drug, SL017, with and without photoactivation. The exploratory objective was to evaluate the efficacy of SL017 with and without photoactivation in the treatment of Actinic Keratosis. The study parameters employed included physician clinical assessment, patient symptomatic assessment, skin photography, blood chemistry, urinalysis, electrocardiogram and skin biopsy. The study was conducted at clinical sites in Edmonton and Montreal.

The study met all the objectives address
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , , ... innovative,cancer therapy. , , ... Dr.Zhaohui Peng is the chairman,chief executive officer, and founder of ... Road, Shenzhen Hi-Tech Industrial Park, Shenzhen, China, , ...
... By Julia Cino, PhD , ... , Over the last ... and place genes into a variety of organisms that are quite different ... organisms is to produce,proteins. Since many proteins are of immense commercial value, ...
... for Culturing Mammalian, Insect, Plant, Bacteria, and Yeast Cells , ... Vyas, Product Manager , New ... 1-800-631-5417 or 1-732-287-1200; bioinfo@nbsc.com, www.nbsc.com/bi5.htm ... T-flasks, or roller bottles have,become the lab standard in most fermentation and cell,culture research ...
Cached Biology Technology:The Genesis of Gendicine: The Story Behind the First Gene Therapy 2The Genesis of Gendicine: The Story Behind the First Gene Therapy 3The Genesis of Gendicine: The Story Behind the First Gene Therapy 4The Genesis of Gendicine: The Story Behind the First Gene Therapy 5The Genesis of Gendicine: The Story Behind the First Gene Therapy 6The Genesis of Gendicine: The Story Behind the First Gene Therapy 7The Genesis of Gendicine: The Story Behind the First Gene Therapy 8The Genesis of Gendicine: The Story Behind the First Gene Therapy 9The Genesis of Gendicine: The Story Behind the First Gene Therapy 10The Genesis of Gendicine: The Story Behind the First Gene Therapy 11The Genesis of Gendicine: The Story Behind the First Gene Therapy 12The Genesis of Gendicine: The Story Behind the First Gene Therapy 13The Genesis of Gendicine: The Story Behind the First Gene Therapy 14The Genesis of Gendicine: The Story Behind the First Gene Therapy 15High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 2High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 3High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 4High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 5High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 6High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 7High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation 8An Easy-to-Use Research Fermentor/Bioreactor 2An Easy-to-Use Research Fermentor/Bioreactor 3
(Date:4/15/2014)... Center in Greenbelt, Md., is home to hundreds ... At Goddard, some of the most cutting-edge Earth ... of that cutting-edge innovation has earned a Goddard ... Society for Anthropology and Geography awards the Vega ... has shown excellence in the fields of physical ...
(Date:4/15/2014)... UC San Diego have succeeded in visualizing the ... for growth and resistance to drought. The achievement ... determine how the hormone helps plants respond to ... continuing increase in the atmosphere,s carbon dioxide, or ... in the April 15 issue of the scientific ...
(Date:4/15/2014)... Zealand,s pastoral landscapes are some of the loveliest in ... Many of the country,s pasture soils have become enriched ... which is then eaten by the cattle and sheep ... New Zealand; cadmium-enriched soils being reported worldwide. , The ... levels in meat and dairy products, human health and ...
Breaking Biology News(10 mins):Goddard scientist receives Vega Medal from King of Sweden 2Biologists develop nanosensors to visualize movements and distribution of plant hormone 2
... step in making artificial life forms from scratch. Using ... membranes, the structural envelopes that contain and support the ... of chemistry at the University of California, San Diego, ... report their success in the Journal of the ...
... leading causes of death. And yet, despite decades ... for most cancers. In addition, disappointing results from ... need for alternative methods. Mathematical modeling ... tumors in terms of differential equations and stochastic ...
... the College of Agricultural Sciences, The Pennsylvania State University, State ... Abstract Submissions: 1 March 2012 -- The Society for ... abstract for presentation at the 45th SSR Annual Meeting to ... Links to the following are to be found on the ...
Cached Biology News:Chemists synthesize artificial cell membrane 2Aiding cancer therapy by mathematically modeling tumor-immune interactions 2Aiding cancer therapy by mathematically modeling tumor-immune interactions 3
... Fixed clamp trays and universal ... Magnetic drive Shaking ... 25 mm amplitude ... to 2000 ml, including Fernbach flasks ...
... fluorescent microscopy-based imaging system that accurately counts ... calculates cell viability, in a single test. ... variability associated with the subjective interpretation of ... EasyCount ViaSure Kit, up to six tests ...
... than western blotting. Get results sooner and save ... gel detection. Eliminates the need for a membrane ... All reagents are ready-to-use. No reagents to prepare ... 2 reagents required. Guarantees a simple to perform, ...
... The CHEF-DR III variable angle system, 220-240 ... greater than 6 Mb DNA fragments by pulsed ... electrophoresis cell, power module, variable-speed pump, 14 x ... comb holder, 15-well, 1.5 mm thick comb, screened ...
Biology Products: